Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

44%

11 trials in Phase 3/4

Results Transparency

50%

11 of 22 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

Phase 2
10(45.5%)
Phase 3
7(31.8%)
Phase 4
4(18.2%)
Phase 1
1(4.5%)
22Total
Phase 2(10)
Phase 3(7)
Phase 4(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT00638651Phase 1Completed

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

Role: collaborator

NCT00979550Phase 2Terminated

The Effects of Aldara as an Adjunct to Laser Treatment

Role: collaborator

NCT01203878Phase 4Terminated

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Role: collaborator

NCT00735462Phase 3Completed

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Role: lead

NCT01055106Phase 2Completed

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Role: lead

NCT01229319Phase 4Unknown

Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

Role: collaborator

NCT00674739Phase 3Completed

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Role: lead

NCT00894647Phase 3Completed

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Role: lead

NCT00189306Phase 3Completed

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Role: lead

NCT00335179Phase 2Completed

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

Role: lead

NCT00668733Completed

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year

Role: lead

NCT00116649Phase 4Completed

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Role: lead

NCT00129519Phase 3Completed

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

Role: lead

NCT00605176Phase 3Completed

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Role: lead

NCT00603798Phase 3Completed

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

Role: lead

NCT00601016Phase 2Completed

A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy

Role: collaborator

NCT00115154Phase 4Completed

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

Role: lead

NCT00117871Phase 2Completed

Study With a Topical Gel to Treat Common Warts in Adults

Role: lead

NCT00115141Phase 2Completed

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Role: lead

NCT00116675Phase 2Completed

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Role: lead